NON-HODGKIN'S LYMPHOMA
Clinical trials for NON-HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for NON-HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Donor immune cells show promise against relapsed blood cancers
Disease control OngoingThis early-phase study tests a new treatment for people with certain blood cancers (lymphoma or leukemia) that have returned after a stem cell transplant. Researchers take immune cells (T cells) from the original stem cell donor, modify them to recognize and attack cancer cells c…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 26, 2026 06:36 UTC
-
New CAR t therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests a new treatment called SC262 for people with Non-Hodgkin's lymphoma that has come back or not responded to other therapies. SC262 is a type of immune cell therapy (CAR T) made from donor cells, designed to target cancer cells. The main goal is to chec…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated May 26, 2026 06:36 UTC
-
New CAR T-Cell combo shows promise for tough lymphoma
Disease control OngoingThis early-phase study tested whether giving patients their own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for treating aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Se…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
Drug combo aims to speed immune recovery in blood cancer patients after transplant
Disease control OngoingThis study tests whether giving palifermin and leuprolide acetate (or degarelix) can help the immune system recover more quickly after a stem cell transplant from a donor. The trial includes 82 adults with blood cancers like leukemia or lymphoma. Researchers will measure CD4+ T c…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New hope for lymphoma patients: experimental drug glofitamab shows promise in early trial
Disease control OngoingThis study is testing a new drug called glofitamab, alone or with another drug (obinutuzumab), in about 940 people whose B-cell non-Hodgkin's lymphoma has come back or stopped responding to standard treatments. The goal is to find the safest and most effective dose and see how we…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New drug duo shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of two drugs, obinutuzumab and ibrutinib, as the first treatment for people with slow-growing non-Hodgkin's lymphoma. The goal is to see how well the drugs shrink or eliminate cancer. About 30 adults with newly diagnosed lymphoma will receive this t…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New imaging agent could light up tumors for better cancer detection
Knowledge-focused OngoingThis early-phase study is testing a tiny amount of a new drug called 124I-PUH71 in 63 people with certain cancers (lymphoma, myeloma, or solid tumors). The goal is not to treat the cancer, but to see how the drug spreads through the body and collects in tumors, and how long it st…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 14:05 UTC